[PharmNews=Eung-Min Kim] Hugel Inc., a leading global medical aesthetics company, has recently hosted a launch seminar for its botulinum toxin Botulax and hyaluronic acid dermal filler Revolax at Holiday Inn Almaty, Kazakhstan, for local dermatologists and plastic surgeons.

Kazakhstan, the largest country in Central Asia, is experiencing about 10% annual growth in the aesthetic industry, driven by a stable economy and a significant increase in population. Hugel plans to actively expand in neighboring Commonwealth of Independent States (CIS) building on its debut in Kazakhstan.

The launch event, titled NEXTGEN Beauty Congress, was held for about 120 medical and aesthetic professionals in Kazakhstan to introduce Botulax and Revolax in the Central Asian country.

Dr. Jonghoon Park, a medical chief at Own Clinic Samseong Branch in Seoul and the guest speaker of the event, delivered a lecture on the clinical efficacy of Botulax and the application of Revolax for Asian facial structure. He also shared clinical cases from Korea to enhance understanding of the combination treatment of botulinum toxin and dermal filler.

“We’re delighted to launch our flagship products Botulax and Revolax in Kazakhstan, the economic center of Central Asia. We will build a stable presence in the local market with sales and marketing activities that create synergy between the toxin and dermal filler products,” a Hugel official said.